Claims for Patent: 9,217,031

Summary for Patent: 9,217,031

Title:	Humanized anti-IL-20 antibody and uses thereof
Abstract:	The present disclosure provides humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.
Inventor(s):	Chang; Ming-Shi (Tainan, TW)
Assignee:	National Cheng Kung University (Tainan, TW)
Application Number:	14/066,018
Patent Claims:	1. A method for treating cancer, comprising administering to a patient in need thereof an effective amount of an humanized antibody capable of binding to human IL-20, the antibody comprises: (i) a heavy chain variable region (V.sub.H), which comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:1 or SEQ ID NO:3 and consists of one or more mutations in one or more framework regions (FRs) in SEQ ID NO:1 or SEQ ID NO:3, and (ii) a light chain variable region (V.sub.L), which comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:5 or SEQ ID NO:7 and consists of one or more mutations in one or more framework regions (FRs) in SEQ ID NO:5 or SEQ ID NO:7 wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, and oral cancer. 2. The method of claim 1, wherein the cancer is breast cancer. 3. The method of claim 1, wherein the V.sub.H comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3. 4. The method of claim 1, wherein the V.sub.L comprises the amino acid sequence of SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:15. 5. The method of claim 3, wherein the V.sub.L comprises the amino acid sequence of SEQ ID NO:5, SEQ ID NO:7, or SEQ ID NO:15. 6. The method of claim 1, wherein the humanized antibody is a full-length antibody. 7. The method of claim 6, wherein the humanized antibody is an IgG antibody. 8. The method of claim 1, wherein the humanized antibody is an antigen binding fragment. 9. The method of claim 1, wherein the subject in need thereof is a human patient having or suspected of having cancer. 10. The method of claim 1, wherein the subject is co-administered with a second anti-cancer agent. 11. The method of claim 10, wherein the second anti-cancer agent is Tomaxifen, Taxol, Erlotinib, Dexasone, or Herceptin.

Details for Patent 9,217,031

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2032-05-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2032-05-22